Vaccines and antibodies up for debate at CDC advisory panel meeting
The meeting, scheduled for June 25-26, will review existing data and vote on RSV and influenza vaccines, along with thimerosal, a preservative used in vials of medicines and vaccines.
Below are some of the companies that make the vaccines that will be discussed at the meeting, according to the final agenda published on the CDC's website.
Sanofi (SASY.PA), opens new tab
Fluzone - The quadrivalent influenza vaccine was approved in 2013 for patients aged six months and older.
Flublok - Approved in 2016 for adults aged 18 and older, replacing the trivalent version licensed in 2013 by offering protection against four influenza strains.
Sanofi reported U.S. sales of $1.66 billion for influenza vaccines in 2024.
AstraZeneca/MedImmune [RIC:RIC:MEDIMV.UL]
FluMist - FDA approved AstraZeneca and partner MedImmune's nasal spray influenza vaccine in September 2024 for self-administration by adults up to 49 years of age, or by a parent/caregiver to individuals aged 2-17 years. The vaccine generated sales of about $258 million in 2024.
CSL Seqirus, part of Australia-based biotech firm CSL Ltd (CSL.AX), opens new tab
FlucelVax - The FDA approved the cell-based influenza vaccine in October 2021 for people aged six months and older.
Afluria - The egg-based influenza vaccine was approved in October 2018 for people aged six months and older.
Fluad - The adjuvanted influenza vaccine was approved by the FDA in February 2020 for people aged six months and older.
The three vaccines combined brought in sales of $1.72 billion in 2024
RSV VACCINES
Sanofi/AstraZeneca (AZN.L), opens new tab
Nirsevimab (Beyfortus) - The FDA approved the antibody, branded as Beyfortus, in 2023 to prevent respiratory syncytial virus (RSV) infections in infants.
Sanofi reported U.S. sales of $1.24 billion for the vaccine in 2024.
Merck ((MRK.N), opens new tab)
Clesrovimab (Enflonsia) - The company gained approval for its RSV-preventing antibody, branded as Enflonsia, in June 2025. The antibody is designed for infants up to one-year olds during their first RSV season, with shipments planned for the 2025-2026 season.
GSK (GSK.L), opens new tab
Priorix - Approved by the FDA for the prevention of measles, mumps, and rubella (MMR) in individuals aged one year and older. It can be administered in two doses or as a second shot following a prior MMR vaccination. GSK reported global sales of $439.96 million for the vaccine in 2024.
MODERNA (MRNA.O), opens new tab
mNEXSPIKE - The next-generation COVID-19 vaccine was approved for aged 65 and above in May 2025.
Spikevax, Moderna's first COVID-19 vaccine, received its initial FDA approval in January 2022. Spikevax brought in total sales of $1.8 billion in 2024.
Pfizer (PFE.N), opens new tab/BioNTech (22UAy.DE), opens new tab
Comirnaty - The COVID-19 vaccine was approved by the FDA in August 2021 for people aged 16 years and older. It generated sales of $5.35 billion in 2024.
Novavax (NVAX.O), opens new tab
Nuvaxovid - The protein-based COVID-19 vaccine was approved by FDA in May 2025 for people aged 65 and older, following nearly five years of regulatory delays and financial uncertainty. The vaccine, Novavax's sole commercial product, generated $682 million in total revenue for 2024, which includes licensing and royalties.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
BBC News
2 hours ago
- BBC News
The deadly cancers left behind by 50 years of success
The number of people surviving cancer has improved hugely in the past 50 years, but experts warn progress has been uneven with some of the cancers with the worst survival rates falling further some, including melanoma skin cancer, 10-year survival is now above 90%, while for all cancers, half of patients can expect to live that long - double the figure in the early a study by the London School of Hygiene and Tropical Medicine said there had been little improvement in those affecting the oesophagus, stomach and lungs - and less than 5% survive pancreatic cancer for 10 government said it was committed to making more progress with a new strategy due soon. The researchers said advances in treatment and earlier detection were behind the improvements in survival seen for many cancer is a perfect example of this, with 10-year survival rates rising from 42% to more than 76% between 1971 and 2018 in England and period saw the introduction of an NHS breast screening programme, plus targeted therapies for different types of breast comparison, the cancers with the lowest survival rates tend to be the hardest to detect and have the fewest treatment pancreatic cancer, the study says these include oesophagus, stomach and lung cancers, which all still have 10-year survival rates below 20%, after only a small amount of progress since the has meant the gap between the cancers with the best and worst survival rates has nearly doubled. 'Amazing job' Matt Black is someone with first-hand experience of how the type of cancer you get makes a huge 2019 the 60-year-old lost his sister, Harriette, to pancreatic cancer, 20 years after his father-in-law died of oesophageal years ago he was diagnosed with bowel cancer which has above average survival rates. Soon after developing symptoms he had surgery and was given the all-clear."NHS staff do an amazing job, but it's such a difficult time to be a cancer patient, especially for those with cancers which aren't easy to spot or treat. "It's so important that there is more research and support for cancer services here, so that more people can be as fortunate as me," says Matt. The researchers also warned that, while overall survival was still improving, the rate of progress had slowed during the 2010s. Longer waits for diagnosis and treatment are thought to be partly to blame. Michelle Mitchell, chief executive of Cancer Research UK, which funded the study, said: "Thanks to research, most patients today are far more likely to survive cancer than at any other point in the past."But the reality is that this progress is slowing – and for some cancers it never got going in the first place."The charity wants the government's forthcoming strategy to focus on:cutting waiting timesearly detection, including full introduction of a lung cancer screening programmeinvestment in research, particularly targeting the most deadly cancersA Department of Health and Social Care spokesman said cancer care was a priority. with some progress already made on waiting times."The national cancer plan will set out how we will improve survival rates further and address the unacceptable variation between different cancer types," he added.
The Independent
4 hours ago
- The Independent
Vegas funeral home which smelled of ‘death' shut down after failing to cremate bodies
A Las Vegas funeral home has shut down after authorities accused it of failing to cremate bodies promptly, sometimes leaving remains for months in unsanitary conditions that one neighbor said caused the business to smell like 'death.' The Nevada State Board of Funeral and Cemetery Services revoked the license of McDermott's Funeral Home and Creation Services last week, finding that the business had not cremated or properly disposed of eight bodies in a 'reasonable period of time.' One body was kept at the facility for over 10 months before being cremated, according to officials. 'The smell was straight up death,' Daran Denny, who owns a tattoo shop nearby, told the Las Vegas Review-Journal. 'I was a medic for 10 years, and I know what death smells like.' McDermott's owner, Chris Grant, said delays in processing were a result of waiting for approval from Clark County Social Services to pay for the treatment of bodies that went unclaimed or abandoned. The Independent has contacted the agency for comment. 'Human nature is: 'Funeral Home got closed. I bet they were doing some scummy stuff,'' he told the paper. 'Nobody thinks that me and my staff lost everything. I just lost a 25-year career. I just lost a business that I've been building for 8½ years. I just lost the ability to even provide for my family.' During a February 2024 site visit, an inspector found eight bodies that hadn't been swiftly processed — Pamala Middlebrooks, Joseph Vocatura, Debi Vince, Catherine Lane-Novak, Lonna Lonning, Teresa John, Lawrence Ponteri and Edward Elliot — all of which had sat in refrigeration units for two months or more. Investigators then found that in all eight cases, the funeral home hadn't filed death records within the lawful 72 hours of death or receiving the bodies, either. One inspector that year described seeing 'three coolers containing numerous bodies that were leaking blood and bodily fluids.' A visit also revealed 'fluids of a body… had dripped onto a body on a lower shelf and onto the floor,' according to documents obtained by KLAS. A McDermott's general manager told the outlet the inspections were 'baseless,' and the funeral board denied the business, which had complaints dating back to 2021 with regulators, the opportunity for 'corrective action.'
Daily Mail
4 hours ago
- Daily Mail
Man, 60, poisoned himself after taking medical advice from ChatGPT
A man was left fighting for his sanity after replacing table salt with a chemical more commonly used to clean swimming pools after following AI advice. The 60-year-old American spent three weeks in hospital suffering from hallucinations, paranoia and severe anxiety after taking dietary tips from ChatGPT. Doctors revealed in a US medical journal that the man had developed bromism - a condition virtually wiped out since the 20th century - after he embarked on a 'personal experiment' to cut salt from his diet. Instead of using everyday sodium chloride, the man swapped it for sodium bromide, a toxic compound once sold in sedative pills but now mostly found in pool-cleaning products. Symptoms of bromism include psychosis, delusions, skin eruptions and nausea - and in the 19th century it was linked to up to eight per cent of psychiatric hospital admissions. The bizarre case took a disturbing turn when the man turned up at an emergency department insisting his neighbour was trying to poison him. He had no previous history of mental illness. Intrigued and alarmed, doctors tested ChatGPT themselves. The bot, they said, still recommended sodium bromide as a salt alternative, with no mention of any health risk. The case, published in the Annals of Internal Medicine, warns that the rise of AI tools could contribute to 'preventable adverse health outcomes' in a chilling reminder of how machine-generated 'advice' can go horrible wrong. AI chatbots have been caught out before. Last year, a Google bot told users they could stay healthy by 'eating rocks' – advice seemingly scraped from satirical websites. OpenAI, the Silicon Valley giant behind ChatGPT, last week announced that its new GPT-5 update is better at answering health questions. A spokesman told The Telegraph: 'You should not rely on output from our services as a sole source of truth or factual information, or as a substitute for professional advice.' Daily Mail have approached OpenAI for comment. It comes after clinical psychologist Paul Losoff told the that dependency on AI robots is becoming a huge risk, and warned against getting too close to ChatGPT. 'One might come to depend and rely on AI so [much] that they don't seek out human interactions,' he said. He explained that this could be especially detrimental for those who may already be struggling with anxiety or depression. Dr. Losoff explained that by using AI, these people may worsen their conditions and experience cognitive symptoms like chronic pessimism, distorted thinking, or cloudy thinking. And that in itself could create further issues. 'Because of these cognitive symptoms, there is a risk that an individual turning to AI may misinterpret AI feedback leading to harm,' he said. And when it comes to people who may be in crisis, this may only exacerbate issues. Dr. Losoff said that there is always a risk that AI will make mistakes and provide harmful feedback during crucial mental health moments. 'There also is a profound risk for those with acute thought disorders such as schizophrenia in which they would be prone to misinterpreting AI feedback,' he said.
